[1] Zeltsman D, Acker MA. Surgical management of heart failure: an overview. Annu Rev Med.2002;53:383-391.[2] Barnard CN.The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town.S Afr Med J. 1967;41(48): 1271-1274.[3] Mascia L, Mastromauro I, Viberti S, et al.Management to optimize organ procurement in brain dead donors.Minerva Anestesiol. 2009;75(3):125-133.[4] 万方数据库.万方医学网[DB/OL].2013-09-03. https://med.wanfangdata.com.cn[5] Medline.Pubmed[DB/OL].2013-09-03.http://www.ncbi.nlm.nih.gov/pubmed/[6] 周长玲.经颅彩色多普勒脑死亡诊断应用的探讨[J].医学影像学杂志,2011,21(10):1567-1569.[7] 苏一家.重型颅脑外伤的临床救治体会[J].中国医学创新,2010, 7(18): 72-73.[8] 王卫民,姜启周,肖国民,等.脑疝进展期患者颅内压动态变化初步探讨[J].中国医师进修杂志,2008,31(5):58-59.[9] 卫生部脑死亡判定标准起草小组.脑死亡判定标准(成人)(修订稿)[J].中国脑血管病杂志,2009,6(4):220-224.[10] Khasati NH, Machaal A, Barnard J, et al.Donor heart selection: the outcome of "unacceptable" donors.J Cardiothorac Surg. 2007;2:13.[11] 李文,江文诗,周稚烨,等.中国器官获取与移植监测网络[J].中华移植杂志(电子版),2012,6(1):5-8.[12] Patel ND, Weiss ES, Nwakanma LU, et al.Impact of donor-to-recipient weight ratio on survival after heart transplantation: analysis of the United Network for Organ Sharing Database.Circulation.2008;118(14 Suppl):S83-88.[13] 王春生,陈昊,洪涛,等.原位心脏移植治疗终末期心脏病141例[J]中华器官移植杂志,2006,27(3):152-155.[14] 陈良万,陈道中,杨国锋,等.61例心脏移植术的供心获取[J].中国胸心血管外科临床杂志,2009,16(4):296-299.[15] Goland S, Czer LS, Kass RM, et al.Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool.J Am Coll Cardiol. 2008;51(12):1214-1220.[16] 洪丰,翁渝国,梁红,等.放宽心脏移植供、受者年龄的可行性研究[J].中华器官移植杂志,2000,21(5)::262-263.[17] Banner NR, Thomas HL, Curnow E, et al.The importance of cold and warm cardiac ischemia for survival after heart transplantation.Transplantation. 2008;86(4):542-547.[18] 黄洁.阜外医院200例心脏移植病人中期生存率和影响因素与ISHLT结果对比分析研究[D].北京:北京协和医学院,2010:8-38.[19] 杨军峰,肖学钧,章庆春,等.无心跳供体心脏移植热缺血时限的实验研究[J].岭南心血管病杂志,2008,14(4):278-281.[20] Scheule AM, Jost D, Beierlein W, et al.Sodium-hydrogen inhibitor cariporide (HOE 642) improves in situ protection of hearts from non-heart-beating donors.J Heart Lung Transplant. 2003;22(12):1335-1342.[21] Hwang H, Arcidi JM Jr, Hale SL, et al.Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application.J Cardiovasc Pharmacol Ther. 2009;14(2): 125-133.[22] 黄雪珊,廖崇先,陈道中,等.免疫诱导治疗预防移植心脏急性排斥反应的临床经验[J].中华胸心血管外科杂志,2004,20(2): 118-119.[23] Fischer JH, Funcke C, Yotsumoto G, et al.Maintenance of physiological coronary endothelial function after 3.3 h of hypothermic oxygen persufflation preservation and orthotopic transplantation of non-heart-beating donor hearts.Eur J Cardiothorac Surg. 2004;25(1):98-104.[24] 王德才.HOE-642联合Nicorandil提高猪心脏停跳供体(NHBD)心脏移植效果实验研究[D].广东:广州医学院,2006:1-2.[25] 马利明,王曦,周云,等.甲泼尼龙琥珀酸钠对脑死亡供体心脏功能保护的研究[J].昆明医科大学学报,2012,33(12):18-21.[26] 陈涛,易定华,王红兵,等.心脏移植28例供体的心肌保护[J].心脏杂志,2006,18(3):361.[27] Deng MC.Cardiac transplantation.Heart. 2002;87(2):177-184.[28] de Jonge N, Kirkels JH, Klöpping C, et al.Guidelines for heart transplantation.Neth Heart J. 2008;16(3):79-87. |